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ABSTRACT 
Cerebral palsy (CP), the most common cause of movement disorders and physical disability 
in children all over the world, is caused by an injury to the developing brain. Although this 
injury is not progressive, the manifestations of the disorder change as the child ages. 
Spasticity and altered viscoelastic properties of the muscle often enhance muscle resistance 
to stretch and the peak spasticity of the calf muscles in children with CP observed at four 
years of age declines thereafter until twelve years of age. The cause of muscle contractures, 
which appear early and progress throughout childhood and adolescence is unclear and 
needs to be elucidated further to help design more effective preventive measures. 
Therefore, the first aim of this thesis was to further characterize muscle pathophysiology in 
children with CP with fixed contractures. 
 
Treatment of patients with CP involves a wide variety of efforts. Standardized and 
objective follow-up, as well as cost effectiveness are of considerable importance. 
Therefore, the second aim here focused on novel tools for clinical evaluation, as well as 
assessment of the economics of switching between two botulinum toxins (BoNT-A) in 
treatment of children with CP. We developed further a three-dimensional test of arm reach 
in typically developing (TD) children and tested the feasibility of this test in young adults 
with CP. We also developed a new approach evaluating the effects of BoNT-A treatment 
involving monitoring the child´s home and school environments with four accelerometers. 
Moreover, we made a controlled switch from one brand of BoNT-A to another in attempt to 
reduce the drug cost without reducing efficacy or duration or exacerbating side-effects. 
 
The major novel findings with respect to muscle pathophysiology are that impaired 
production of ribosomes probably explains, at least in part, the deficient growth of skeletal 
muscle observed in children with CP and that levels of pro-inflammatory cytokines are 
elevated in their muscles. The latter alteration contributes to both inhibition of growth and 
expansion of the extracellular matrix and perhaps to the development of muscle 
contractures as well in children with CP. In addition, in the muscles of these children the 
number of satellite cells was reduced, the amount of intramuscular collagen situated around 
bundles of muscle fibers elevated and expression of the fatigable and fast Myosin Heavy 
Chain IIx isoform in wrist flexors higher in comparison to TD children.  
 
The major findings with respect to the development of novel tools for assessment and cost-
effectiveness are that the 3D Reach Test for the arms exhibits excellent inter- and intra-
session reliability in TD children, as well as excellent feasibility and reliability in a pilot 
study on young adults with CP. Moreover, monitoring children with CP in their own 
environment with four accelerometers following BoNT-A treatment reveals previously 
unknown effects on physical activity, effects not detected by routine clinical follow-up, 
such as a decline in ambulatory activity after injection into the legs. When the BoNT-A 
preparation used previously was replaced by another commercial BoNT-A product, the 
parents reported the treatment of their children with CP to be equally effective, while the 
cost was 41% lower with few, similar and transient side-effects.  
 
In conclusion, the present investigations provide new information on the pathophysiology 
of muscle in children with cerebral palsy that can help improve our understanding of 
contracture formation. The 3D Reach Test and post treatment monitoring with 
accelerometers are promising new tools for evaluation of the effects of treatment on reach 
and everyday movement. The cost of BoNT-A treatment can be reduced considerably by 
switching to another brand without compromising either the effect or patient safety.  
 LIST OF SCIENTIFIC PAPERS 
 
I. Gantelius S, Hedström Y, Pontén E. 
Higher expression of myosin heavy chain IIx in wrist flexors in cerebral 
palsy.  
Clin Orthop Relat Res 2012, 470(5):1272-1277. 
 
II. von Walden F, Gantelius S, Liu C, Borgström H, Björk L, Gremark O, Stål P, 
Nader GA, Pontén E.  
Muscle contractures in patients with cerebral palsy and acquired brain injury 
are associated with extracellular matrix expansion, pro-inflammatory gene 
expression, and reduced rRNA synthesis.  
Muscle Nerve 2018, 58(2):277-285. 
 
III. Gantelius S, Borgström H, Mao H, Pontén E, Gutierrez-Farewik EM.                                                                                                   
A new method of three-dimensional analysis of upper extremity reach suitable 
for cerebral palsy.  
In manuscript. 
 
IV. Gantelius S, Vikerfors S, Jansson Edqvist J, von Walden F, Hagströmer M, 
Pontén E.   
New and unexpected insights to the effects of treating children with cerebral 
palsy with botulinum toxin based on accelerometer monitoring in their own 
environment.  
Submitted. 
 
V. Tedroff K, Befrits G, Tedroff CJ, Gantelius S. 
To switch from Botox to Dysport in children with CP, a real world, dose 
conversion, cost-effectiveness study.  
Eur J Paediatr Neurol, 2018;22(3):412-8 
 
  
CONTENTS      
1 Introduction ................................................................................................................. 1 
1.1 Etiology and brain lesion characteristics ............................................................ 1 
1.2 Classification ..................................................................................................... 2 
1.3 Muscle physiology and pathology ..................................................................... 3 
1.4 Contracture development ................................................................................... 5 
1.5 Reduced reach and evaluation of the arms ......................................................... 6 
1.5.1 The Melbourne assessment of unilateral upper limb function ................ 6 
1.5.2 The Assisting Hand Assessment ............................................................ 6 
1.5.3 Shriners Hospital for Children Upper Extremity Evaluation .................. 7 
1.5.4 The Modified Ashworth Scale ............................................................... 7 
1.6 Motion analysis ................................................................................................. 7 
1.7 Accelerometry ................................................................................................... 7 
1.8 Treatment options targeting muscle ................................................................... 7 
1.9 Treatment with botulinum toxin ........................................................................ 8 
1.10 The Economics of Botulinum toxin treatment ................................................... 9 
2 Aims .......................................................................................................................... 11 
2.1 Paper I ............................................................................................................. 11 
2.2 Paper II ............................................................................................................ 11 
2.3 Paper III ........................................................................................................... 11 
2.4 Paper IV........................................................................................................... 11 
2.5 Paper V ............................................................................................................ 11 
3 Materials and Methods .............................................................................................. 13 
3.1 Participants ...................................................................................................... 13 
3.1.1 Paper I .................................................................................................. 13 
3.1.2 Paper II ................................................................................................ 13 
3.1.3 Paper III ............................................................................................... 13 
3.1.4 Paper IV ............................................................................................... 13 
3.1.5 Paper V ................................................................................................ 13 
3.2 Methods ........................................................................................................... 13 
3.2.1 Clinical examination, surgical procedures and injection procedure ...... 13 
3.2.2 Muscle biopsies ................................................................................... 14 
3.2.3 Protein separation and quantification ................................................... 15 
3.2.4 Satellite cells, intramuscular collagen and muscle fiber size ................ 15 
3.2.5 RNA and protein extraction, cDNA synthesis and qRT-PCR .............. 15 
3.2.6 Western blotting ................................................................................... 15 
3.2.7 Analysis of arm movements ................................................................. 15 
3.2.8 Accelerometry...................................................................................... 17 
3.2.9 Switching the brand of BoNT-A .......................................................... 18 
3.3 Statistical analyses ........................................................................................... 19 
3.3.1 Paper I .................................................................................................. 19 
3.3.2 Paper II ................................................................................................ 19 
3.3.3 Paper III ............................................................................................... 19 
3.3.4 Paper IV .............................................................................................. 19 
3.3.5 Paper V ................................................................................................ 19 
3.4 Ethical considerations ...................................................................................... 20 
4 Results And discussion ............................................................................................. 21 
4.1 Paper I ............................................................................................................. 21 
4.2 Paper II ............................................................................................................ 21 
4.3 Paper III .......................................................................................................... 23 
4.4 Paper IV .......................................................................................................... 24 
4.5 Paper V............................................................................................................ 25 
5 Limitations ................................................................................................................ 27 
6 Summary and conclusions ........................................................................................ 29 
6.1 Paper I ............................................................................................................. 29 
6.2 Paper II ............................................................................................................ 29 
6.3 Paper III .......................................................................................................... 29 
6.4 Paper IV .......................................................................................................... 30 
6.5 Paper V............................................................................................................ 30 
7 Future perspectives ................................................................................................... 31 
8 Populärvetenskaplig sammanfattning ....................................................................... 33 
9 Acknowledgments .................................................................................................... 35 
10 References ................................................................................................................ 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LIST OF ABBREVIATIONS 
ABI 
ACPR 
AHA 
ANOVA 
BoNT-A 
CDC 
cDNA 
COPM 
CP 
cps 
CPUP 
DAPI 
DNA 
ECM 
ECRB 
ECRL 
ECU 
EMG 
FCR 
FCU 
acquired brain injury 
Australian Cerebral Palsy Register 
Assisting Hand Assessment 
analysis of variance 
Botulinum NeuroToxin Type A 
Centers for Disease Control and Prevention 
complementary deoxyribonucleic acid 
Canadian Occupational Performance Measure 
cerebral palsy 
counts per second 
Cerebral Pares UppföljningsProgram (Follow-Up Program) 
4´,6-diamidino-2-fenylindole 
deoxyribonucleic acid 
extracellular matrix 
extensor carpi radialis brevis 
extensor carpi radialis longus 
extensor carpi ulnaris 
electromyography 
flexor carpi radialis 
flexor carpi ulnaris 
GMFCS 
ICC 
IL-6 
IL-1b 
JIA 
Gross Motor Function Classification System 
interclass correlation coefficient 
Interleukin-6 
Interleukin-1b 
juvenile idiopathic arthritis 
MACS 
MAS 
MA2 
MCP3 
MRI  
Manual Ability Classification System 
Modified Ashworth Scale 
Melbourne Assessment 2 
third metacarpophalangeal joint 
Magnetic Resonance Imaging 
MSTN 
mTOR 
MyHC 
NCAM 
PEDI 
PIP 
POL 1 
pROM 
qRT-PCR 
QUEST 
rDNA 
RNA 
ROM 
myostatin 
Mammalian Target of Rapamycin 
myosin heavy chain 
Neural Cell Adhesion Molecule 
Pediatric Evaluation of Disability Inventory 
proximal interphalangeal joint 
DNA polymerase 1 
passive range of motion 
quantitative Real Time-Polymerase Chain Reaction 
Quality of Upper Extremity Skills Test 
ribosomal deoxyribonucleic acid 
ribonucleic acid 
range of motion 
rRNA 
SC 
SCPE 
SD 
SDC 
SDR 
SDS-PAGE 
SEK 
SEM 
SHUEE 
SLL 
TD 
TGF-beta 
TIF-1A 
TNF 
U 
UBF 
3D 
ribosomal ribonucleic acid 
satellite cell 
Surveillance of Cerebral Palsy in Europe 
standard deviation 
smallest detectable change 
Selective Dorsal Rhizotomy 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Swedish crown 
standard error of measurement 
Shriners Hospital Upper Extremity Evaluation 
Stockholms Läns Landsting (Stockholm County Council) 
typically developing 
transforming growth factor-beta 
transcription initiation factor-1A 
tumor necrosis factor 
units 
upstream binding factor 
three-dimensional 
  1 
 
1 INTRODUCTION 
Today, 17 million people worldwide suffer from cerebral palsy (CP). Most children with 
CP will survive until adulthood. Despite an improved survival rate, life expectancy is still 
lower than in typically developing (TD) children [1]. Childhood CP is the most common 
cause of physical disability and movement disorders, with a prevalence of 2-3 per 1000 live 
births [2], more common in boys than girls [3-5]. Despite major advances in neonatal care 
and obstetrics during the last four decades the overall prevalence of CP has not declined 
[1], perhaps due, at least in part to the increased survival of children born at lower 
gestational age [6]. The prevalence of CP among children born preterm is particularly high 
[7]. 
 
Over the years a number of attempts to define and classify CP have been made. Spastic CP 
was first described by the orthopedic surgeon William Little in 1862 as the result of an 
injury to the nervous system acquired during a difficult birth. The initial term “Little´s 
disease” [8] was replaced thirty years later by the term cerebral palsy when Sir William 
Osler wrote the book “The Cerebral Palsies of Children” [9]. Sigmund Freud was the first 
to propose that cerebral palsy could also be caused by intra-uterine events [10]. During the 
second half of the 20th century, Lesley Mutch and colleagues [11] defined CP as “an 
umbrella term covering a group of non-progressive, but often changing, motor impairment 
syndromes secondary to lesions or anomalies of the brain arising in the early stages of 
development”.  
 
The present definition of CP focuses not only on this motor disorder per se, but includes 
accompanying disturbances: “Cerebral Palsy describes a group of disorders of the 
development of movement and posture, causing activity limitations, which are attributed to 
non-progressive disturbances that occurred in the developing fetal or infant brain. The 
motor disorders of cerebral palsy are often accompanied by disturbance of sensation, 
perception, cognition, communication, and behavior, by epilepsy, and secondary 
musculoskeletal problems” [12]. The etiology of the accompanying brain lesion is 
multifactorial and may involve genetic disorders and malformation, disturbance of cerebral 
circulation, infection, inflammation and trauma [13-16]. The brain injury is acquired during 
antenatal, perinatal or early postnatal period [1]. In 2005, Bax and collaborators (the 
Executive Committee for the Definition of Cerebral Palsy) [17] proposed that the first two 
or three years of life may be concerned rather than specified time limits meaning that the 
disturbance resulting in CP is assumed to happen before the affected function, e.g. walking 
or manipulation of objects, has developed. Since it is sometimes difficult to identify a 
neurological abnormality in a very young child and brain lesions in pre-school children are 
associated with similar sequelae, the Australian Cerebral Palsy Register (ACPR) has chosen 
five years as the upper age limit for occurrence of the brain lesion [18]. Although the brain 
injury itself is non-progressive, the manifestations of the disorder change with time [12].  
1.1 ETIOLOGY AND BRAIN LESION CHARACTERISTICS 
Depending on when, rather than how or why, during this time span the injury occurred 
different areas will be susceptible to injury, corresponding to the concept of selective 
vulnerability. A wide range of etiological risk factors, maternal, pregnancy or child related, 
has been identified. However, only rarely, such as in severe perinatal or postnatal asphyxia, 
will CP be caused by a single factor. More commonly is the etiology multifactorial and 
several causative pathways has been identified. Some, identified risk factors for the 
development of CP are maternal obesity, infections occurring during pregnancy or 
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postnatal, multiple pregnancies, low birth weight, injury, immunization i.e. Rh or A-B-O 
immunization, placental dysfunction and neonatal stroke [19-22]. The Apgar score [23] has 
been shown to inversely correlate to risk of CP in children born at term [24].  
 
As an effect of the selective vulnerability of the growing brain, lesions that occur early in 
pregnancy, during the first and second trimester, frequently result in brain malformation 
irrespective of the etiological factors. In late second, and early third trimester, white matter 
damage of immaturity (WMDI), including periventricular lesions, are common. In late 
pregnancy and around the time of birth cortical, subcortical, and basal ganglia gray matter 
lesions are more frequent. Bax and co-workers [19] found brain malformations in about 
10%, white-matter damage in about 40% and gray matter lesions in about 10% of children 
with CP. White matter damage of immaturity is the characteristic lesion seen in cerebral 
palsy associated with preterm birth [25], preterm birth being an important risk factor for 
cerebral palsy [1]. Dyskinetic CP is associated with basal ganglia lesions seen in full-term 
children with severe birth asphyxia or postnatally acquired CP [19, 26]. In no less than 10% 
of children with CP a normal MRI is seen [19].  
1.2 CLASSIFICATION 
The classification of CP by the Surveillance of Cerebral Palsy in Europe (SCPE) [27], now 
utilized worldwide, states that the predominant motor disorder should be categorized as 
spastic, dyskinetic or ataxic and the anatomical distribution determined to be uni- or 
bilateral. In three Swedish studies, unilateral spastic CP accounted for 35-45% and bilateral 
spastic CP for 35-40%. Dyskinetic CP was found in 12-15% and 3-8% were diagnosed with 
ataxia [28-30].  
 
The Gross Motor Function Classification System (GMFCS) [31] and Manual Ability 
Classification System (MACS)  [32] classify the functional abilities of children with CP in 
daily life which is useful clinically. In both of these systems, level I designates the children 
least affected and level V those most severely affected. Children classified as GMFCS level 
I can walk independently while those in GMFCS level III use wheelchairs (manual or 
electric) themselves for longer distances, but can walk with a hand-held walking aid. 
Children classified as GMFCS level V are severely limited in mobility and must be 
transported in a wheelchair by others [31].  
 
Those at MACS level I handle objects easily and successfully, while children at MACS 
level III handle objects with difficulty and need help to prepare and/or modify activities. At 
MACS level V children either cannot handle objects at all or have a severely limited ability 
to perform even simple actions and therefore require total assistance [32]. Arner and co-
workers [30] report 64% of children with CP independent in age-relevant manual activities 
(MACS I-II) and 14% with no active hand function or as total dependent on others in daily 
activities (MACS V). MACS classifies the overall ability to handle objects, not the function 
of each hand separately [32]. For children one to four years of age, the Mini-MACS 
classification is used in a similar manner to that for older children [33]. Hand function in 
individuals with CP can also be assessed according to the House classification system, 
where 0 reflects no use of the hand, 1-3 different levels of passive helper hand, 4-6 different 
levels of active helper hand, and 7 and 8 the ability of the hand to manipulate objects [34-
36]. 
 
Motor dysfunctions associated with CP can be divided into two main categories: Positive 
dysfunctions involve pathology added to normal motor behavior, e.g., spasticity and 
musculoskeletal malformations; while with negative motor dysfunctions, the motor 
repertoire fails to develop normally, resulting in e.g., muscle weakness, paresis and central 
  3 
dyscoordination as well as co-contraction and mirror movements indicating deficiencies in 
sensorimotor control [37].  
 
In addition, the Surveillance of Cerebral Palsy in Europe allows categorization of 
impairments accompanying CP, e.g., cognitive impairment, attention deficit, problems with 
vision and hearing, and emotional and behavioral disorders [27]. The lifestyle of children 
with CP is more sedentary with lower levels of physical activity [38, 39], a potential cause 
of secondary health problems. Physical activity has been associated with positive health 
outcomes in children both with and without disabilities [39]. Peterson and co-workers [40, 
41] observed a significantly elevated prevalence of diabetes, hypertension, coronary heart 
disease, stroke, joint pain and arthritis among adults with CP.  
1.3 MUSCLE PHYSIOLOGY AND PATHOLOGY 
Skeletal muscle of children with CP differs from that of TD children in a variety of ways. 
Their total muscle mass is reduced and the muscles in their affected arms and legs are 
weak, short and thin [42-44]. Furthermore, there is more variability in the size of muscle 
fibers [45, 46] and a lower capillary density in muscles of children with CP [47]. Moreover, 
magnetic resonance imaging (MRI) reveals more intramuscular fat [48], and reduction in 
muscle volume, cross-sectional area and length [49].  
 
Increased resistance to passive muscle stretch is common in children with CP. This 
phenomenon involves both a neuronal component, spasticity, and a mechanical or non-
neuronal component, consisting of changes in elasticity and viscosity [50]. One definition 
of spasticity commonly used has been formulated by Lance: “a motor disorder 
characterized by a velocity dependent increase in tonic stretch reflexes (‘muscle tone’) with 
exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex” [51]. 
Sanger and colleagues [52] define spasticity as “hypertonia in which one or both of the 
following signs are present: 1) resistance to externally imposed movement increases with 
increasing speed of stretch and varies with the direction of joint movement, and/or 2) 
resistance to externally imposed movement rises rapidly above the threshold speed or joint 
angle”.  
 
Spasticity of the calf muscles peaks at four years of age and declines thereafter until the age 
of twelve [53]. However, the reduced passive range of motion (pROM) involving 
alterations in the visco-elastic properties of muscles, that many children with CP develop 
worsens continuously throughout childhood and adolescence, becoming more evident 
during puberty [54, 55], a process referred to as contracture development [56, 57]. 
Approximately one third of children with CP develop contractures in the arms [57]. The 
passive stiffnes, secondary to an upper motor neuron lesion [58-60] is altered in both 
plantar flexors and forearm muscles [44].  
 
The sarcomere is the smallest contractile unit of skeletal muscle. Tandem repeats of 
sarcomeres form myofibrils and parallel myofibrils form muscle fibers that are held 
together in bundles surrounded by the perimysium, part of the extracellular matrix (ECM). 
The sarcomere is defined as the segment between two Z-lines where the actin filaments are 
anchored. The force in a contracting muscle is generated when the motor protein myosin 
interdigitates, between actin filaments, shortening the sarcomere [61]. Conversely, when 
the muscle stretches, the sarcomere lengthens.  
 
With increasing age and progressive contracture development, the sarcomeres in the 
muscles of children with CP become longer [62]. For example, the sarcomeres in the flexor 
carpi ulnaris (FCU) is extremely long when a wrist with a flexion contracture is held in a 
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neutral position [63]. A reduction in the number of sarcomere in series might explain to this 
phenomenon [64-66].  
 
Myosin is composed of two heavy (MyHCs) and two light chains. The isoform of myosin 
present determines the velocity of contraction and endurance of the muscle fibers. Muscle 
fibers with much MyHC I, typically found in muscles responsible for postural control, are 
slow with extensive endurance, those with much MyHC IIx contract rapidly but are easily 
fatigued, whereas fibers with a high content of MyHC IIa contract rapidly and exhibit 
intermediate endurance [67]. 
 
Various stimuli influence the expression of MyHC. In general, voluntary use of a muscle, 
irrespective of intensity, down-regulates MyHC IIx [68] and electrical stimulation can also 
alter expression of MyHC. Paretic skeletal muscle resulting from a spinal cord injury 
expresses equal amounts of MyHC IIa and MyHC IIx, but following electrical stimulation, 
there is an almost complete dominance of MyHC IIa [69]. These findings indicate that 
neuronal signaling exerts an important impact on the expression of myosin and, thus, on the 
type of muscle fiber. In the muscles of children with CP, the muscle fibers shift from the 
slow to fast phenotype [70, 71], with a higher proportion of fibers containing MyHC IIx 
[47], which has been proposed to be due to both inactivity and altered neuronal signaling.  
 
Furthermore, the content and quality of the extracellular matrix (ECM) in the muscles in 
individuals with CP are altered. The ECM within skeletal muscle is composed primarily of 
collagen [72] and the area fraction of ECM in individuals with CP is enhanced [73]. 
Booth and co-workers [74] showed that children with CP, involving severe spasticity and 
contractures demonstrate more collagen in the knee extensor vastus lateralis than both those 
with less severe CP and TD children. de Bruin and collaborators [75] found this increased 
amount of collagen mainly around the bundle of muscle fibers in the form of a thickening 
of the perimysial ECM. Examination by ultrasound reveals an increased echo intensity in 
the skeletal muscle of children with CP suggestive of an increased content of collagen [76]. 
Laminin and collagen IV, components of the basal membrane, are up-regulated in muscles 
with fixed contractures, suggesting that changes in the ECM are neither limited to classical 
isoforms of collagen nor restricted to the perimysium [77] [78]. 
 
Skeletal muscle grows primarily through hypertrophy of existing muscle fibers [79, 80] and 
involves increased synthesis of proteins, mainly actin and myosin, which depends on the 
status and number of the ribosomes [81]. Thus, a growth stimulus elevates the biogenesis of 
ribosomes before any elevation in protein content can be detected [82-85]. The rate-limiting 
step for ribosome production and cell growth [86-88] is thought to be the transcription of 
genes encoding ribosomal (r)DNA by RNA polymerase I. 
 
Satellite cells (SC) are stem cells belonging to a heterogeneous lineage of myogenic 
progenitor cells responsible for the postnatal growth and regeneration of skeletal muscle. 
Since they are terminally differentiated and mature myofibers cannot regenerate, the pool of 
SC is thus essential for muscle repair and regeneration [89, 90]. Hamstrings muscles with 
fixed contractures in children with CP contain fewer SCs than these same muscles in TD 
children [91]. A reduced number or dysfunction of SCs has been suggested to underlie the 
impaired growth of muscles in cases of CP, potentially contributing to contracture 
development [91].  
 
This proposal is supported by recent experiments indicating that in adult mice satellite cells 
are not required for hypertrophy, whereas young mice do require satellite cell-mediated 
myonuclear accretion to undergo hypertrophy [92]. In addition, a reduction in the number 
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of satellite cells does not impede the addition of sarcomeres in series, but instead reduces 
the number of myofibers and decreases the muscle area fraction [93]. On the other hand, 
chronic loading of a muscle with a reduced number of satellite cells triggers excessive 
ECM production [93, 94].   
 
Children with CP often display characteristic positioning of the affected arm, with flexion 
of the elbow, wrist, and fingers and pronation of the forearm [95]. This typical pattern is 
deleterious to hand usage, with such improper positioning of the elbow and wrist impairing 
both reach and grip function [96]. Wrist flexors and extensors work as agonists to stabilize 
the wrist during grip [97]. The poor selective motor control leads to inadequate adjustment 
of muscle tone in children with CP. Their wrist flexors demonstrate a larger cross-sectional 
area and are stronger than wrist extensors, pulling the wrist into the flexed position often 
observed [98]. One arm is often more affected than the other, since the brain injury is 
usually asymmetric, making the arm less affected dominant. Other deviant postures 
typically observed in children with CP include ankle equinus, deficient knee extension, hip 
adduction (with or without scissoring of the legs), deficient hip extension, and, on occasion, 
hip dislocation [99]. Contracture, co-contraction, spasticity, weakness and poor selective 
muscle control influence the positioning of the limbs of these children, both during activity 
and at rest.  
1.4 CONTRACTURE DEVELOPMENT 
One-third of children with CP will develop an arm contracture [57]. Muscle contractures 
develop continuously throughout childhood and adolescence in these children, although 
more rapidly during puberty [54, 55]. The MACS level is the strongest predictor of 
contracture formation in the arm, with children at MACS level V exhibiting a 17-fold 
higher risk of such development than those of MACS level I [57]. The various explanations 
proposed include a mismatch between bone and muscle growth, alterations in neural 
activation,  mechanotransduction, tensional homeostasis, micro-vascularization, genetics 
and epigenetics [100]. A flexed joint position in itself [101], with a resultant loss of 
sarcomeres [62] has also been suggested to result in contractures. 
 
Spasticity has been proposed to cause shortening of joint flexors [102], even though the 
stretch reflex is often enhanced in both the joint flexors and extensors of children with CP. 
However, even with successful elimination of spasticity (e.g. by selective dorsal 
rhizotomy), range of motion continues to decrease [103]. Furthermore, after BoNT-A 
treatment and successful reduction of spasticity, contractures continue to develop [104]. If 
spasticity is the primary cause of contracture development, elimination of spasticity should 
slow down or stop this process but this is not the case. 
 
A primary growth defect has been proposed to contribute to contracture development in CP 
muscle [100, 105] since the muscles of very young children with CP grow more slowly 
prior to such development [56]. Herskind and colleagues [56] detected a reduced volume of 
gastrocnemius muscle in children with CP already at 15 months of age, with no 
concomitant reduction in the rate of bone growth. Furthermore, the GMFCS level and thus, 
the degree of walking and weight bearing was correlated with the volume of the 
gastrocnemius muscle [56].  
 
Depending on the muscle architecture, post-natal growth of skeletal muscle could involve 
an increase in the cross-sectional area rather than the length [79, 80]. Therefore, a failure to 
increase muscle fiber thickness rather than longitudinal growth of the fiber could also be of 
relevance to contracture formation. The hypothesis that a reduced growth rate is one cause 
of contracture formation, is supported by the lower numbers of satellite cells and therefore, 
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reduced potential for growth, in the hamstring muscle of children with CP. Potentially, the 
associated increases in laminin and collagen contents could function as a mechanical barrier 
that blocks the migration of satellite cells during activation [78]. 
 
The skeletal muscle of adult patients with myositis and muscular dystrophies are fibrotic, 
i.e., contain an elevated amount of ECM around individual fibers, at the expense of 
functional tissue [106]. With these muscular disorders elevated levels of cytokines 
commonly precede fibrosis [107]. The existence of similar pro-inflammatory and pro-
fibrotic networks has been suggested by transcriptional studies of the skeletal muscle of 
children with CP [78, 108]. Pro-inflammatory cytokines influence the size of skeletal 
muscles negatively, promoting atrophy and hampering growth [109]. Thus, attenuated 
growth of skeletal muscle and elevated collagen content result from elevated levels of pro-
inflammatory cytokines and might explain, at least in part, contracture formation in 
children with CP. 
 
It should be noted that most biochemical and histological investigations on muscle from 
individuals with CP have been performed on biopsy material obtained during surgical 
procedures intended to alleviate fixed contractures. Thus, it remains unclear whether the 
changes described above in muscles from children with CP are the causes or consequences 
of the contracture.  
1.5 REDUCED REACH AND EVALUATION OF THE ARMS 
The active range of motion (ROM) of the shoulder, elbow, wrist and fingers in combination 
with the total length of the arm determines the three-dimensional (3D) reach of the arm, 
which is important for many daily activities, i.e., eating and moving the hand towards the 
axilla and perineum to care for personal hygiene. The ability to reach out for objects is also 
an important requirement for independent living. The arms of children with CP often have a 
limited 3D reach due to the brain injury and resultant typical positioning of the arm and 
hand [110].  
 
To facilitate and standardize clinical evaluation of the arms of children with CP, e.g., 
following BoNT-A treatment, a number of tools have been developed. 
1.5.1 The Melbourne assessment of unilateral upper limb function  
The Melbourne assessment of unilateral upper limb function [111] involves video-based 
evaluation and was initially developed for 5-15-year-old children with neurological 
impairments. Four major aspects of movement are assessed: 1) the pROM of all upper limb 
joints, 2) accuracy of reach, 3) dexterity of finger movements, and 4) the fluency and 
smoothness of movement. These four aspects are observed during completion of 16 tasks, 
using one hand at a time, selected to mimic everyday activities [111]. After the 
development into The Melbourne Assessment 2 (MA2) [112] assessment of children 2.5-15 
are possible. After removal of two test items 14 items are left. The MA2 also offers a 
possibility to use the four sub-scales for range, accuracy, fluency and dexterity separately.  
 
1.5.2 The Assisting Hand Assessment 
The Assisting Hand Assessment (AHA), developed for children with unilateral arm 
disabilities, measures how effectively the affected hand is used for bimanual activities, 
which, for these children, might be the most important aspect of hand function. First created 
as a valid instrument for children between the ages of 18 months and 12 years [113], 
subsequent development of the Assisting Hand Assessment for Adolescents (Ad-AHA) 
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[114]  and the mini-AHA [115] now allow scoring between range 8 months to 18 years of 
age. 
1.5.3 Shriners Hospital for Children Upper Extremity Evaluation 
The Shriners Hospital for Children Upper Extremity Evaluation (SHUEE), a video-based 
tool for children with hemiplegic cerebral palsy, includes spontaneous functional and 
dynamic positional analysis and assesses the ability to perform grasp and release [116]. 
1.5.4 The Modified Ashworth Scale 
The Modified Ashworth Scale (MAS) assesses resistance during passive stretch and is 
easily used in clinical practice as a measure of spasticity. The scale is ordinal, ranging from 
0 = no increase in muscle tone to 4 = the joint is rigid [117]. Bohannon and Smith [117] 
reported good reliability whereas Mutlu and colleagues recommend great caution when 
interpreting assessments with the MAS [118]. Ansari et al [119] claim that the MAS does 
not assess spasticity reliably. 
1.6 MOTION ANALYSIS 
In children with CP, several methods for evaluation of the arms are available, although 
some of these are to some extent subjective and time-consuming [120-123]. Analysis of 
arm movement is in many ways more challenging than gait analysis, since arm movements 
are voluntary and more varied than walking which is more automatic and consistent. 
Protocols for 3D movement analysis of arm movements in children with cerebral palsy 
have been developed, although more than one method is required to obtain full functional 
assessment of upper extremity function [124-127], since no test covers all abilities and 
difficulties and none provide quantitative data for use in connection with follow-up during 
childhood. Moreover, only kinematics (the motion of body segments in relation to each 
other) can be obtained from the analysis of arm movements. Gait analysis has been used as 
a tool in the evaluation of children with CP since the 1990´s [128, 129]. 
1.7 ACCELEROMETRY 
Accelerometers measure the rate of change in velocity with respect to time, usually 
expressed in SI units (Système international (d'unités), International System of Units) as 
acceleration is meters per second squared (m/s2). Today´s clinical accelerometers are the 
size of a wristwatch and allows portable monitoring of body movements in one, two or 
three axes [130], capturing large amounts of data for storage or transmission [131]. 
Although, accelerometers do not measure all physical activity, such as isometric exercises, 
most energy is consumed during dynamic physical activity, such as walking and running, 
which they do measure reliably [132]. Accelerometers enable a reliable and valid 
measurement of physical activity in walking children with CP [133, 134] and have been 
employed to quantify both the duration and intensity of unilateral and bilateral use of the 
arms by adult stroke patients [135]. Four accelerometers placed on both wrists, around the 
waist and around one ankle can monitor changes in both walking and bimanual activity and 
have been utilized to evaluate stroke rehabilitation [136]. 
1.8 TREATMENT OPTIONS TARGETING MUSCLE 
Treatment often targets primarily one component of the resistance to stretch: Spasticity can 
be reduced by intramuscular injection of botulinum toxin type A (BoNT-A) [137], oral or 
intrathecal baclofen [138] or selective dorsal rhizotomy (SDR) [103]; while splinting and 
serial casting, for example, targets the viscoelastic component [139]. When non-invasive 
treatment or injection of BoNT-A proves inadequate, a variety of different surgical 
treatments can be offered to the child [101]. Surgery alters the viscoelastic component of 
resistance and the range of motion, indirectly alleviating spasticity by changing the tension 
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of the muscle spindles. Surgical correction of contractures involves, for example, tendon 
lengthening, release or lengthening of the affected muscle–tendon unit, myofascial 
lengthening, tenotomies, recession of the aponeurosis, or tendon transfers that restore the 
balance around the joint [140, 141]. The common Green transfer involves transfer of a 
tendon from an overactive wrist flexor to weaker wrist extensors in order to balance the 
wrist [142]. In severe cases of wrist flexion contracture, resection of the proximal carpal 
bones in combination with a wrist arthrodesis may be the more effective solution [143]. All 
treatment options involves some risk of permanent loss of force and/or movement [144] or 
with only temporary effect [145]. Co-contraction and poor selective motor control are 
difficult, if not impossible, to treat. 
1.9 TREATMENT WITH BOTULINUM TOXIN 
The short-term reduction in spasticity of both the arms [146] and legs [147] following 
intramuscular injections of BoNT-A is well documented [148]. Indeed, this is one of the 
few interventions that reduce spasticity effectively [137]. In a Norwegian population-based 
study, almost 70% of all children with spastic CP underwent BoNT-A treatment [149]. The 
CPUP (Cerebral Pares Uppföljnings-Program), the Swedish CP follow-up program and 
healthcare registry, reveals that 26% of children with CP received BoNT-A treatment 
during a two-year period [150], with similar proportions in the years 2010 and 2015 [150].  
 
When BoNT-A is injected into the spastic muscle, precision is commonly ensured by 
electrical stimulation or guidance by electromyography (EMG) or ultrasound. BoNT-A is a 
polypeptide that cleaves a protein required for vesicle fusion in the motor nerve ending 
thereby preventing the neurosecretory vesicle from fusing with the synaptic plasma 
membrane and inhibiting the release of acetylcholine. This interferes with nerve impulses 
and reduces muscle activity in a reversible manner. The effect is observed days after 
injection and maximal after approximately three weeks, lasting typically for a total of 3-6 
months [151]. The magnitude of this chemical denervation is dependent on the nature of the 
disorder and dose [151-153]. Recovery of muscle function following injection of BoNT-A 
has been attributed to axonal sprouting and subsequent re-innervation of the muscle fibers 
[154].  
 
BoNT-A enhances the passive range of motion of the knee joint, although this improvement 
is sometime lost with time [155]. Furthermore, in combination with physiotherapy and the 
use of orthoses, BoNT-A improves gait [156]. In case of arms, evidence in favor of 
improved function and enhanced usage is inconclusive [157], and post-injection training is 
necessary for functional improvement [146]. The side-effects of BoNT-A treatment are few 
and transient. Pain and weakness have been reported following treatment of the legs of a 
pediatric population [158, 159].  
 
Mainly because of co-contraction, arm swing is often reduced in children with CP [160], 
which slows down walking speed. Typically, the arms become more active and arm 
movements become larger as walking speed increases, indicating arm involvement in 
gaining walking speed [160]. Therefore, improving arm swing in ambulatory children 
might improve their general ability to participate in physical activities. Moreover, more 
symmetrical gait is desirable in terms of appearance for many teenagers. BoNT-A treatment 
can also relieve pain and ease of the care of non-ambulatory children most affected with no 
manual ability (GMFCS V, MACS V). Attenuation of pain through intramuscular 
injections of BoNT-A is believed to act both via reduction of spasticity and through 
alternative pharmacological pathways [161].  
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There is no evidence that therapeutic doses of BoNT-A injected into the muscle cross the 
blood-brain barrier [162]. However, BoNT-A might exert an indirect effect on the central 
nervous system through interference with function of intrafusal fibers in the injected 
muscles. Subsequent sensory afference to the spinal cord may influence the brainstem and 
cortical areas and the resulting feedback changes might then, in turn, affect muscles other 
than the ones initially injected [162]. In addition, BoNT-A appears to act directly on the 
spinal cord, probably influencing retrograde axonal trafficking of active neurotoxin. Thus, 
BoNT-A probably alters the excitability of spinal pathways, causing central chemo-
denervation via retrograde axonal transport to the spinal cord [163].  
 
BoNT-A treatment requires co-operation between different professionals, with a team often 
consisting of pediatric orthopedic surgeons, child neurologists, physiotherapists, 
occupational therapists, specialized pediatric nurses and anesthesiologists. The injections 
are commonly administrated by the pediatric orthopedic surgeons or pediatric neurologists. 
Intra-muscular injections are painful and anesthesiologists may provide anesthesia or 
analgesia with nitrous oxide. In the clinical follow-up, physiotherapists and occupational 
therapists focus on the child’s attainment of goals, everyday activities, pROM and 
spasticity. In addition, a physiotherapist evaluates gross motor activity and an occupational 
therapist manual ability. Individual goals for the treatment are set by the team together with 
the child and his/her parents. In a 24-months follow-up after injection, attainment of goals 
increased gradually up to 12 months and was thereafter maintained [164]. Consensus 
documents concerning doses and which muscles to treat are available [151, 165]. The team 
must also plan for possible future interventions, e.g., additional BoNT-A treatment, serial 
casting, orthoses, training and/or surgery. 
 
Clinical follow-up typically takes place in a hospital or habilitation center, i.e., an 
environment with which the child is somewhat unfamiliar, so it is somewhat unclear to 
what extent the findings reflect performance, level of physical activity (PA) and usage of 
the arms in a day-to-day context. Indeed, children and their parents sometimes describe 
features not revealed by the clinical evaluation. Furthermore, it remains unknown whether 
the extent of PA or arm movements are affected by injecting BoNT-A into the legs. In 
addition, it is of interest to know whether the arms swing more actively only when walking 
or during other manual activities as well. 
1.10 THE ECONOMICS OF BOTULINUM TOXIN TREATMENT 
The Centers for Disease Control and Prevention (CDC) in the USA [166] has estimated the 
medical costs for a child with CP to be 10 times higher than those for a TD child. For the 
50% of all children with CP who also demonstrate an intellectual impairment [167],  these 
costs were 26 times higher [166]. However, when comparing the cost of different drugs 
(e.g. biosimilars), the price is not the only factor that needs to be taken into consideration. 
From a clinical and socioeconomic perspective, the effect and duration are equally 
important and of course, any adverse effects must also be taken into account. Since BoNT-
A treatment involves a large professional team, the total cost includes much more than 
simply that of the drug. The time parents take off from work also impacts the total 
socioeconomic cost, making the duration of treatment of importance. Few studies on the 
health economics on this topic have been reported [168] and only two studies involved 
switching between BoNT-A products [169, 170].  
 
The BoNT-A preparations currently available for clinical use differ with respect to price 
and potency [165, 171] and, as a consequence, each has its own dosing recommendations 
and they cannot be simply replaced by one another [172]. Two of these products, Botox® 
(Allergan, Irvine, CA, USA) and Dysport® (Ipsen Limited, Slough, Berkshire, UK) are 
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more commonly used in children with CP. To date, there is no generally accepted factor for 
translating one unit of Botox® into a unit of Dysport®, with ratios of 1:2-1:11 having been 
proposed [173]. Obviously, this conversion factor influences the total cost. 
 
In Sweden, pediatric health care is funded fully by taxes and free of charge to the individual 
patient. County Councils procure drugs for a specific indication at the best possible price. 
Health care providers choice on what drug to use is based on recommendations or decisions 
associated with this procurement process. In 2014, the Stockholm County Council (SLL), 
which provides health care for about 2.5 million inhabitants, procured Botox® and Dysport® 
utilizing a conversion factor of 1:3 at the cost of 1332 SEK for 100 U (in packages of 10 
vials) and 1099 SEK for a single 300 U vial, respectively. 
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2 AIMS 
The general aims of this thesis were to explore muscle composition to improve our 
understanding of the mechanisms of contracture formation in connection with CP and to 
investigate two aspects of BoNT-A treatment of children with CP, i.e., whether another 
follow-up approach can provide information that traditional post-injection follow-ups do 
not and to compare the efficacy, duration of improvement, side-effects and cost of 
switching from Botox® to Dysport®. Another aim was to develop further the analysis of 
arm movement for monitoring the effect of treatment.  
 
The specific aims were as follows: 
2.1 PAPER I 
To compare the MyHC composition of the forearm muscles of children with and without 
CP and to relate this composition to functional classifications and clinical findings.  
2.2 PAPER II 
To compare gene expression data and histological findings in muscle from children with CP 
to those of TD children in an attempt to explain contracture formation. We focused 
specifically on factors related to growth and size homeostasis, i.e. expression of genes 
related to ribosome biogenesis, negative regulators of muscle mass and the numbers of 
satellite cells in skeletal muscle. We also examined the levels of mRNAs encoding pro-
inflammatory cytokines and factors involved in collagen synthesis as well as the 
intramuscular content of collagen.  
2.3 PAPER III 
To develop a three-dimensional reach test and evaluate its intra- and inter-session reliability 
in TD children. A secondary aim was to compare the 3D reach of the dominant and non-
dominant hand of young adults with CP as a test of the utility of this method and its 
feasibility and reliability in this group.  
2.4 PAPER IV 
To determine whether monitoring of children with CP following BoNT-A injection with 
accelerometers at home and at school can provide information that traditional follow-ups do 
not. We were specifically interested in whether other effects of BoNT-A would be detected 
and whether injection elevated the duration of ambulatory activity and/or diminished the 
differences in movement of the arms more and less affected.  
2.5 PAPER V 
To evaluate switching from one brand of BoNT-A (Botox®) to another (Dysport®), with a 
conversion factor of 1:2, for treatment of children with CP, with special focus on cost per 
treatment and whether parents perceived the treatments as equivalent with respect to 
efficacy, duration and side-effects. 
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3 MATERIALS AND METHODS 
3.1 PARTICIPANTS 
3.1.1 Paper I 
Nine children with CP (age 8–17 years, mean 14; 2 girls, 7 boys) scheduled for tendon 
transfer of the forearm were recruited. Five TD children (age 7–13 years, mean 10; 2 girls, 
3 boys) in need of surgery for open reduction of a forearm fracture served as the control 
group.   
3.1.2 Paper II 
Twenty children and adolescents (age 9-18 years, mean 15.5 years; 3 girls, 17 boys) with 
spasticity (18 with CP, 2 with an ABI at 7 and 8 years of age) scheduled for surgical 
lengthening of the biceps tendon were included. Muscle samples from ten TD children and 
adolescents (age 7-21 years, mean 15.2 years; 2 girls, 8 boys) and who had suffered an 
accidental death were obtained post-mortem.  
3.1.3 Paper III  
A convenience population of 34 TD children (age 5-18 years, mean 11; 17 girls, 17 boys) 
was utilized. Complete data on 32 and 30 children was collected for evaluation of intra-
session and inter-session reliability respectively. For four children data from one session 
was incomplete and therefore excluded from the corresponding reliability evaluation. To 
evaluate the utility of the 3D Reach Test in a clinical setting, a convenience sample of five 
young adults with unilateral spastic CP (age 18-24 years, mean 20.5; 1 girl, 4 boys,) was 
examined.  
3.1.4 Paper IV 
Twelve ambulatory children (age 4-13 years, mean 7.9; 5 girls, 7 boys) with CP (GMFCS I-
III) scheduled to receive a BoNT-A injection in the leg muscles with or without injection in 
the arm most affected were included. All were injected in the legs and five in one arm as 
well.  
3.1.5 Paper V 
A total of 170 children, 159 with CP (age 5-14 years, mean 9, 65 girls, 94 boys) who 
received BoNT-A treatment to reduce increased muscle tone due to spasticity or dystonia 
(at the Department of Pediatric Orthopedic Surgery, Astrid Lindgren Children's Hospital, at 
Karolinska University Hospital between September 1, 2014, and December 31, 2015) were 
evaluated. During this period, the children with CP visited the hospital 341 times for 
treatment. A total of 278 (2014) and 301 (2015) treatments administered for CP, post-
traumatic brain injury, hereditary dystonia or stroke were used to calculate the 
cost/treatment.  
3.2 METHODS 
3.2.1 Clinical examination, surgical procedures and injection procedure 
In Paper I, the hand function of individuals with CP was classified according to House  
[34-36], ambulatory ability assessed according to the GMFCS [31] and the ability to handle 
objects in daily life classified according to the MACS [32]. The maximal passive extension 
of the wrist was measured with the fingers flexed. 
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Fracture surgery in TD children was performed under general anesthesia within 24 hours of 
the trauma. These patients had had their arm immobilized in the emergency room. Biopsies 
were taken from exposed muscles in the middle 1/3 of the forearm, one flexor and one 
extensor in all cases. Specifically, the flexor carpi ulnaris (FCU, 4 cases), the flexor carpi 
radialis (FCR, 1 case); the extensor carpi radialis brevis (ECRB, 3 cases), the extensor carpi 
ulnaris (ECU, 2 cases) were sampled. All muscles were sampled with good visibility and no 
visible injury at the site of biopsy. Biopsies from wrist extensor and flexor muscles of the 
children with CP were obtained during surgery under general anesthesia, after exposure, but 
prior to the tendon transfer. All surgery was performed following fasting for 6-8 hours.   
 
In Paper II, the maximal extension of the elbow prior to surgery was measured with a 
goniometer by an occupational therapist with all patients included exhibiting an extension 
deficit of >10°. Samples of the biceps brachii muscle were obtained intra-operatively under 
general anesthesia, after exposure but before tendon lengthening. Control samples of the 
biceps brachii were obtained from TD children and adolescents during autopsy within 24 
hours of death.  
 
In Paper III, bilateral arm length, the dominant arm, sex and age were recorded. Arm length 
was determined from the acromion to the metacarpophalangeal joint 3 (MCP3) and to the 
proximal interphalangeal joint 3 (PIP3) with a measuring tape.  
 
In Paper IV, the BoNT-A (Botox®, Allergan, Irvine, CA, USA) injections were given by 
pediatric orthopedic surgeons employing EMG guidance and/or electrical stimulation with 
the child under nitrous oxide analgesia. Treatment goals were set by physiotherapists and 
occupational therapists together with the child and his/her parents and the pediatric 
orthopedic surgeon chose which muscles to inject on the basis of these specific goals. In the 
case of the arms, this decision-making was also supported by the results of the AHA [113], 
the SHUEE [116] or the Melbourne Assessment [111]. When treating the legs, Botox® was 
diluted to 50 IU/ml and for the smaller muscles in the arm, to 100 IU/ml. The dose per 
individual muscle and patient was determined in accordance with prevailing guidelines, 
with maximal doses of 12 IU/kg body weight and 50 IU/injection site [174]. Prior to, and as 
well as three weeks and three months after injections a physiotherapist and an occupational 
therapist assessed, among other parameters, passive range of motion (pROM) and spasticity 
according to the Modified Ashworth Scale (MAS) [117].   
 
In Paper V, all children were assessed by a team consisting of pediatric orthopedic 
surgeons, child neurologists, physiotherapists, occupational therapists both prior to 
treatment, and three weeks and three months post-injection. Treatment goals were set and 
followed up as described for Paper IV. Additional follow-up measures included spasticity 
according to the Modified Ashworth Scale (MAS) [117], joint range of motion (ROM), the 
AHA [113], the Melbourne Assessment [111, 112], SHUEE [116] and assessment of pain 
for patients with pain reduction as goal. The majority of injections were administered with 
nitrous oxide (N2O) analgesia, a few under general anesthesia, and an even smaller number 
with only local or oral analgesia. All injections were administrated with EMG or ultrasound 
guidance. 
3.2.2 Muscle biopsies 
All muscle biopsies were frozen immediately in either isopropane (Paper I) or isopentane 
(Paper II) cooled with liquid nitrogen and stored thereafter at -80° C until being analyzed. 
For histochemistry, muscle samples from children with CP and TD children were cut into 
7μm or 10 μm sections, depending of the staining planned, at -20° C using a cryostat.  
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3.2.3 Protein separation and quantification 
SDS-PAGE was used for protein separation in Paper I. The levels of the MyHC I, IIa, and 
IIx isoforms were determined from silver-stained 6% SDS-PAGE [175] where three distinct 
bands could be identified as MyHC I (migrating fastest), IIa, and IIx isoforms (slowest). 
The gels were scanned in a soft laser densitometer to determine the relative proportion of 
each isoform. Results from this procedure has previously been found to correlate well with 
MyHC content quantified with immuno-histochemistry [176].  
3.2.4 Satellite cells, intramuscular collagen and muscle fiber size 
Satellite cells were identified in sections fixed and stained according to Lindström et al. 
[177] utilizing a light microscope equipped with excitation filters connected to a camera. 
From each cross-section, the number of satellite cells per number of nuclei was determined. 
A satellite cell was defined as fulfilling the following criteria: positive staining with 
CD56/NCAM (Neural Cell Adhesion Molecule); possessing a nucleus stained by DAPI 
(4´,6-diamidino-2-phenylindole); and in a sublaminar position, as confirmed by the laminin 
staining. 
 
Intramuscular collagen content was visualized by Sirius Red staining according to 
Junquiera et al. [178], the sections washed and dehydrated as described by de Bruin et al 
[75] and the cross-sections quantified with a light microscope and camera. Custom-made 
software for analysis of collagen content and fiber size was developed. Calibrated areas 
were measured excluding regions with fibers cut longitudinally or folded sections, as well 
as those containing larger nerves and blood vessels. For each cross-section, the total tissue 
area and the area staining specifically for collagen were determined and the percentage area 
of collagen calculated. 
 
Sections stained with Picro Sirius Red were also used for measuring fiber size. Four areas 
chosen randomly, each containing 150-200 fibers were examined and fiber size assessed by 
image analysis. Again, regions containing fibers cut longitudinally or folded sections were 
excluded.  
3.2.5 RNA and protein extraction, cDNA synthesis and qRT-PCR 
Skeletal muscle tissue was homogenized and RNA and protein extracted utilizing standard 
techniques. RNA was quantified spectrophotometrically and its integrity assessed by 
agarose gel electrophoresis. The protein concentration was determined with a colorimetric 
assay. RNA was reverse-transcribed to cDNA and gene expression evaluated by 
quantitative real-time polymerase chain reaction (qRT-PCR). For each target gene, all 
reactions were run in triplicate. Relative levels of expression were obtained by 
normalization to the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA. 
3.2.6 Western blotting 
In Paper II, samples containing equal amounts of protein were separated by SDS-PAGE 
and Western blotting then performed using standard techniques with primary antibodies 
targeting Transcription Initiation Factor-1A (TIF-1A), Upstream Binding Factor (UBF) and 
GAPDH. Secondary antibodies were diluted in blocking buffer. Immuno-reactive bands 
were visualized using infrared fluorescence and band density determined with the Image 
Studio software.  
3.2.7 Analysis of arm movements 
The voluntary ROM of the arms was captured by an 8-camera optoelectronic motion 
capture system (Vicon Oxford, UK). Nineteen spherical reflective markers were attached to 
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the hands, arms, head and trunk [179]. All anatomic positions that could easily be palpated. 
The head markers were attached to a headband. 
 
 
 
Figure 1. Marker placement (Photo by the author, published with permission from the child and parents) 
 
RFHD = right front head; LFHD = left front head; CLAV = jugular notch; STRN = xiphoid process; LBHD = 
left back head; RBHD = right back head; C7 =  spinous process of the seventh cervical vertebra; T10 = 
spinous process of the tenth thoracic vertebra; RBAK = one spinous process between the seventh cervical and 
the tenth thoracic vertebras; LSHO = left acromion; RSHO = right acromion; LELB = left radial epicondyle; 
RELB = right radial epicondyle; LWRA = dorsal midpoint of the wrist, left arm; RWRA = dorsal midpoint of 
the wrist, right arm; LFIN = third metacarpophalangeal joint, dorsal left hand; RFIN = third 
metacarpophalangeal  joint, dorsal right hand; LPIP3 = third proximal interphalangeal joint, dorsal left hand; 
RPIP3 = third interphalangeal joint, dorsal right hand 
 
The overall reach volume for each arm was determined while the children performed arm 
movements following standardized instructions. Each arm of the TD children was tested 
three times. The first two sessions, performed with the original marker placement, were 
used to evaluate intra-session reliability. The third session, performed after removal of all 
markers, a short break and subsequent marker replacement, was used to evaluate inter-
session reliability, in comparison to the second trial. For comparison of the left and right 
arms, data from the first session with each participant were used. Participants with CP 
performed only the two first sessions without marker removal and replacement. 
 
A coordinate system around the trunk was created, with the origin defined as the point 
between the dorsal marker on the spinous process of the seventh cervical vertebrae and the 
ventral marker between the medial ends of the clavicles. Distal markers were placed on the 
elbow, wrist, third metacarpophalangeal joint and third proximal interphalangeal joint as 
above. 
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Figure 2.  
Superior view of the virtual shape, unilateral (left) CP 
 
The 3D reach volume for each of these markers with respect to the trunk coordinate system 
was computed as a virtual shape generated by its trajectory and the volume of that shape 
computed using a Convex Hull algorithm [180] that computes the smallest volume which 
includes all positions of the marker along the trajectory. To enable inter-subject 
comparisons this volume was divided by arm length cubed. The standard deviations (SD) of 
the volumes were determined from the 3 trials. 
 
In order to determine the distribution of this reach volume relative to the subject’s body, the 
overall volume was divided into to two hemispheres, each of which was subsequently 
divided into four quadrants. 
3.2.8 Accelerometry 
The physical activity of the subject in his/her own home and school environments was 
monitored by four uniaxial accelerometers attached with soft elastic bands to both wrists, 
the waist and around the right ankle [136] with the sum of acceleration recorded by each 
monitor being converted into “counts” [181, 182]. Since walking and running require 
reciprocal movement by both legs, one accelerometer on the ankle in combination with one 
on the waist is sufficient to monitor ambulatory activity. With accelerometers on both 
wrists, the dominant and the non-dominant sides can be compared. Total body activity was 
evaluated from the information provided by the accelerometer around the waist [133, 134, 
183].  
 
Physical activity was assessed during waking hours for four consecutive days, including 
two weekdays and an entire weekend [184] both prior to the injections as well as three 
weeks and three months later. The data were obtained separately from the four 
accelerometers [135] were synchronized with respect to time and processed employing a 
customized program developed in MatLab® (MathWorks, Natick, MA, US). For analysis, 
active wear time was calculated by subtracting non-wear time from the total recording time 
(raw data).  
 
The data for each day were analyzed independently dividing active time into time spent 
performing ‘voluntary manual activity’ or ‘ambulatory activity’ (walking, running, 
jumping). Voluntary activity was defined as an acceleration of the waist <25 counts/second 
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(cps) [183] together with acceleration of one or both arms. Ambulatory activity was defined 
as acceleration of the waist >25 cps together with acceleration of the leg [183]. Bimanual 
activity was defined as both arms demonstrating an acceleration >0 cps and the waist an 
acceleration <25 cps, and expressed as a percentage of the time spent performing voluntary 
activity. The time spent in physical activity is expressed relative to the total active wear 
time and its intensity as mean acceleration (cps) 
 
 
Table 1. Definition of activities 
 
active time= total recording time subtracted with non-wear time, cps=counts/second, t=total time spent 
performing an activity, ta=time spent in ambulatory activity, sum=the sum of acceleration (counts), tdom=total 
time when acceleration of the dominant arm was >0, tndom=total time when acceleration of the non-dominant 
arm was >0, tv=time spent by the arms performing voluntary activity, tsim=time when acceleration of both 
arms was >0, W=waist worn accelerometer, L=leg worn accelerometer 
3.2.9 Switching the brand of BoNT-A 
Following a process of procurement by the Stockholm County Council, Botox® was 
replaced by Dysport®. We carried out a prospective population-based observational study 
on all children with CP who received BoNT-A treatment to reduce muscle tone elevated 
due to spasticity or dystonia. Baseline data on the duration and effect of the previous 
injection were collected for four months prior to the switch, so that each child contributed 
with evaluation data of 1-2 treatments with Botox® and 1-3 treatments with Dysport® 
during the study period.  
 
Parents were asked to evaluate the duration and magnitude of the effect (on an ordinal scale 
of 0 = “no effect” to 10 “best possible effect”) of the previous injection, as well as side-
effects. The duration of the effect of each treatment was documented by the attending 
physician using a standardized protocol, in which he/she also recorded the goal of the 
treatment (functional goals, pain reduction and/or facilitating activities of daily living) 
together with the weight of the child, the muscles injected and dose and dilution of the 
product injected. The cost of the of BoNT-A in 2014 (Botox®) and 2015 (Dysport®) to the 
Activity Definition 
Ambulatory activity  
(W>25 cps + L>0 cps) 
 
ta/active time 
mean acceleration of the leg sum(L)/ta 
mean acceleration of the dominant arm sum(dom)/ta 
mean acceleration of the non-dominant arm sum(ndom)/ta 
mean acceleration of the waist sum(W)/ta 
Voluntary activity of arms  
(W<25 cps + armdom>0 cps and/or W<25 cps + armndom>0 cps) 
 
tv/active time 
time spent using the dominant arm (%) tdom/tv 
time spent using the non-dominant arm (%) tndom/tv 
mean acceleration of the dominant arm sum(dom)/tv 
mean acceleration of the non-dominant arm sum(ndom)/tv 
time spent using the arms simultaneously 
tsim/tv 
mean acceleration of the dominant arm during simultaneous use of 
both arms 
sum(dom)/tv 
mean acceleration of the non-dominant arm during simultaneous use 
of both arms 
sum(ndom)/tv 
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Dept. of Pediatric Orthopedic Surgery at Astrid Lindgren Children's Hospital was acquired 
from the Stockholm County Council and then divided by the number of treatments per year 
to obtain a cost/treatment. 
3.3 STATISTICAL ANALYSES 
3.3.1 Paper I 
Differences between the flexors and extensors of the wrist were analyzed as related values 
with the Wilcoxon signed-ranks test. Differences between the muscles of patients with CP 
and controls were examined with the Mann-Whitney test. Spearman’s rank correlation 
coefficient was used to test for correlation between the percentage of each isoform of 
MyHC and passive wrist extension or the GMFCS, MACS, and House classifications. We 
used the PASW1 Statistics 18.0 (IBM, Armonk, NY, US) for all analyses. Data were 
reported as means ±SD and the level of significance set at p<0.05.  
3.3.2 Paper II 
Differences between levels of mRNA, protein or collagen content were assessed with the 
Mann-Whitney-Wilcoxon test. Statistical analyses were performed with the Prism 7 
Software (GraphPad Software, Inc, CA, US) and the level of significance set at p<0.05.  
3.3.3 Paper III  
The distribution of the data was shown to be approximately normal and parametric 
statistical analyses were therefore applied.  
 
The Interclass Correlation Coefficients (ICC) (SPSS 24, IBM, NY, US) for the total volume 
within reach of the four markers (elbow, wrist, MCP3 and PIP3) and for the volume 
encompassed by these markers in each sector were calculated. Intra-session reliability was 
computed from the volumes measured in trials 1 and 2 and inter-session reliability from the 
volumes measured in trials 2 and 3, in both cases using a two-way random model of 
absolute agreement. The ICC value range from 0 to 1 with a value of 1 reflecting a perfect 
reliability. The reliability findings were interpreted according to Fleiss [185] with an ICC 
greater that 0.75 considered excellent.  
 
To assess the disagreement between measurements, the standard error of measurement 
(SEM) was calculated. In addition, the smallest detectable change (SDC) was calculated to 
evaluate the new procedure. To analyze for differences in the volumes measured with the 
dominant and the non-dominant arms, a general linear model for analysis of variance 
(ANOVA) for repeated measures was employed. The level of significance was set as 
p<0.05. 
3.3.4 Paper IV 
To account for repeated measures and within-subject variance and correlated data, a linear 
mixed model was used to analyze outcomes with introduction of an interaction term to 
evaluate heterogeneity. The statistical analyses were performed with the IBM SPSS 
Statistics 24 software (IBM, NY, US) and the level of significance set at p<0.05.  
3.3.5 Paper V 
The characteristics of the patients and their disease were described, employing median and 
range or relative frequencies for continuous and categorical data, respectively. Doses of 
BoNT-A are presented as means ±SD. 
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3.4 ETHICAL CONSIDERATIONS 
Prior to the collection of material and data, all studies were approved by the regional ethical 
committee of Karolinska Institutet. Both parents, and, whenever possible, the children 
themselves (depending on age and mental capacity) received written and oral information 
about the planned study and provided informed consent before entering. 
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4 RESULTS AND DISCUSSION  
4.1 PAPER I 
The most important findings of Paper 1 were as follows: 1) The wrist flexors of children 
with CP contain a higher proportion of the fast and fatigable MyHC IIx than TD children.  
2) Wrist flexors contain a higher proportion of MyHC IIx than wrist extensors. 3) The wrist 
flexors of children with CP contain a reduced proportion of the fast MyHC IIa isoform. 4) 
Wrist flexors contain a lower proportion of MyHC IIa than wrist extensors. 5) The level of 
MyHC I in children with CP was lowered in their wrist extensors only. 6) No correlations 
between the levels of MyHC isoforms and GMFCS, MACS, House classifications or 
passive extension of the wrist were observed.  
 
Children with CP often move one or both arms involuntarily as a result of co-contraction or 
because of mirror movements (i.e., involuntary simultaneous and similar movement of the 
opposite hand while performing a task with one hand [186]. Usually, mirror movements are 
more pronounced in the less affected hand while using the more affected hand is being used 
[187]. In cases of major brain injury resulting in structural reorganization of the 
corticospinal tract, the main motor pathway, an ipsilateral, rather than contralateral control 
of the hand most affected is seen more often [188]. Through such reorganization, the 
manual ability can be maintained, but at the expense of more frequent mirror movements 
[186].  
 
The reduced arm movement in children with CP during both manual activities and walking 
(arm swing) may explain for the upregulation of MyHC IIx observed which is in line with 
previous reports [189]. This expression is higher when the disability is more severe and 
spasticity worse [176], since voluntary activation is thought to down-regulate MyHC IIx to 
a greater extent than either involuntary contractions or mirror movements [60, 67].  
 
We found no correlation between the levels of the different isoforms of MyHC and the 
functional classification (GMFCS, MACS or House) or severity of contracture. Either our 
study population was too small to allow any such correlation to be detected or other factors 
exert a stronger influence on the expression of MyHC. The wide variation in frequency and 
intensity with which the arms are utilized in daily life, alterations in brain signaling that 
result in different degrees of muscle spasticity and stiffness, or perhaps other trophic factors 
secreted by motor nerves might be involved. Our findings on changes in contractile proteins 
in children with CP motivate further research on: motor control, weakness and contracture 
development in this context.  
4.2 PAPER II  
The most important observations in Paper 2 were as follows: 1) Ribosome biogenesis in 
skeletal muscle is impaired in children with CP. 2) The expression of genes encoding pro-
inflammatory cytokines is elevated in the skeletal muscle of children with CP. 3) The 
number of satellite cells in their muscles is decreased, and 4) The amount of collagen 
surrounding bundles of muscle fibers and the levels the products of genes involved in 
collagen production are higher in these children.  
 
The growth of muscles in children with CP is impaired compared to that in TD children, as 
shown in several cross-sectional studies [42, 48, 190]. Skeletal muscle associated with CP 
is not only thinner and weaker, but also stiffer [44], all three important contributors to the 
reduced range of motion observed [56]. The anabolic response of skeletal muscle and their 
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development of hypertrophy is largely dependent on the number of ribosomes they contain 
[84, 85], which essentially determines the rate of protein synthesis [81].  
 
Mechanical loading of skeletal muscle cells enhances their production of ribosomes [82, 
83]. Moreover, in newborn mice, inadequate nutrition results in fewer ribosomes and 
slower synthesis of skeletal muscle protein, resulting in stunting [191]. Indeed, inadequate 
nutrition and subsequently inhibited growth are well-recognized problems in children with 
CP as well [192].  
 
The skeletal muscle of children with CP/ABI was found to contain significantly reduced 
levels of two transcription factors essential for ribosome biogenesis, i.e., Transcription 
Induction Factor-1A (TIF-1A) and Upstream Binding Factor (UBF). Consistent with these 
findings, the level of the 45S pre-ribosomal ribonucleic acid (pre-rRNA) transcript in these 
muscles was also reduced, as was the level of mature 28S ribosomal ribonucleic acid 
(rRNA). Therefore, we propose that the slower growth of children with CP may, at least in 
part, result from lowered translational capacity of skeletal muscle due to altered 
neurological signaling and/or inadequate nutrition [193]. 
 
The health and function of skeletal muscle also depend on the satellite cells they contain 
and we found 40% fewer satellite cells in children with CP/ABI than in TD children, in 
agreement with previous reports on the legs of the former [91, 194]. Recently, the necessity 
of satellite cells for hypertrophy of skeletal muscle has been questioned. Genetically 
modified mice, whose satellite cells have been ablated during adulthood respond normally 
to a two-week hypertrophic stimulus. However, the situation in the young and growing 
animal differs: When satellite cells were deleted from these same mice at a younger age, 
satellite cell-mediated addition of myonuclei was required for muscle hypertrophy, 
indicating that these cells are indeed needed for skeletal muscle hypertrophy in the growing 
individual [92].  
 
Further, studies on mice indicate that in addition to their roles in the growth and repair of 
skeletal muscle, satellite cells are also involved in regulating production of the ECM [93]. 
The observation of an expansion of perimysial extracellular matrix in association with a 
31% increase in intramuscular collagen content in connection with CP/ABI agrees with the 
higher levels of the transcripts of genes involved in collagen production that we observed 
(CTGF, TGFB1, TGFBR2, LTPBP1, LOX). We also observed a twofold increase in the 
level of COL1A mRNA. The dual role in muscle protein synthesis and ECM production, 
shown so far only in mice, motivates further studies on the potential involvement of 
satellite cells in contracture development in humans.  
 
Skeletal muscle disorders such as myositis and muscular dystrophies are characterized by 
impaired growth and an increase in the amount of ECM at the expense of functional muscle 
tissue, driven in part by cytokines [107, 195]. The present investigation revealed that in 
muscles of children with CP/ABI the levels of cytokines that can modulate the expression 
of genes involved in both hypertrophy and collagen production were elevated. Moreover, 
the level of messenger RNA (mRNA) encoding transforming growth factor-beta (TGF-
beta), which up-regulates expression of myostatin (MSTN), a potent negative regulator of 
muscle mass [196] was enhanced in these same children. Indeed, their level of MSTN 
mRNA was more than doubled.  
 
MSTN signaling results in muscle atrophy by suppressing protein synthesis and promoting 
protein degradation and impairing cell proliferation [197, 198]. Furthermore, MSTN is 
involved in regulating skeletal muscle fibrosis [199] and has negative effects in vitro on the 
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proliferation of satellite cells from both mice and humans [107, 200]. In addition, MSTN 
regulates fibroblast proliferation and secretion of components [201]. Although the 
expression of pro-inflammatory genes in the muscle of children with CP was elevated, there 
was no inflammatory cell infiltration, as found in Duchenne muscular dystrophy or myositis 
[202]. Therefore, we propose that contracture development and expansion of the ECM in 
connection with CP represent a distinct pathophysiology. 
4.3 PAPER III 
The major findings in Paper III were as follows: 1) The 3D Reach Test for the arms 
exhibits excellent inter- and intra-session reliability in TD children as well as 2) excellent 
feasibility and reliability in a pilot study on five young adults with CP.  
 
The aim here was to develop a simple, but robust 3D Reach Test for one aspect of arm 
functionality. The test was designed to measure the overall reach and relate the location of 
this volume to the positions of the trunk and head. In this particular case, we evaluated the 
reliability of the test in TD children, and performed a pilot study on its feasibility and 
applicability in young adults with CP.  
 
Both the intra- and inter-session reliability are excellent, with ICCs for total volume of 
0.82-0.90 (elbow, wrist, MCP3, PIP3) and the inter-session ICCs 0.80-0.93 (elbow, wrist, 
MCP3, PIP3), respectively. There was no difference between the right and left arm with 
respect to any of the four total volumes of reach (elbow, wrist, MCP3, PIP). The ipsilateral 
anterior superior and inferior volumes together account for approximately 50% of the total 
volume. For the different sectors, the ICC for intra-session reliability was 0.23-0.96 (mean 
0.74) and for inter-session reliability 0.43-0.97 (mean 0.74).  
 
The test demonstrated excellent reliability in young adults with CP, both with respect to 
overall and sector volumes. For this group, ICCs for the intra-session reliability were 
between 0.98-0.99 for total volume (elbow, wrist, MCP3, PIP3), and between 0.67-0.99 
(mean 0.93) for the 8 different sectors. The volumes of reach were significantly lower for 
the non-dominant than the dominant arm. The ipsilateral sectors represented a larger 
proportion of the total volume and there was a larger difference between the volumes of the 
ipsilateral and contralateral sectors in the case of the non-dominant than dominant arm. For 
the wrist, MCP3 and PIP3 markers, the total volume of the dominant arm was twice as 
great. The even higher ICC for this group could be attributed to their age (these subjects 
were older and could followed instructions more closely, but also to the arm movements 
typical for people with CP. Whether reliability is correlated with age remains to be 
determined. In all cases, even for the dominant arm, the total volumes for all markers 
(elbow, wrist, MCP3 and PIP3) were larger in TD children than in those with CP.  
 
The anatomic landmarks utilized here for marker placement are well-defined and easy to 
palpate. Indeed, the high inter-session reliability confirms that this placement is 
reproducible, strengthening the test’s applicability as a routine tool for research or clinical 
use. Measurements, marker placement, practice and data capture for each arm took an 
average of 10 minutes overall to perform and no one reported any discomfort during the 
test. The 3D Reach Test is highly standardized, minimizing the risk for bias originating 
from the evaluation or situation. Division of the obtained 3D reach volume obtained into 
sectors makes it possible to see the change in the location of this volume as well, 
information that could be of importance when evaluating arm surgery.  
 
In light of its excellent reliability, we believe that the 3D Reach Test could be a valuable 
tool for evaluating the effect of treatment effect in patients with limited arm movement, 
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e.g., those with CP. This test can be used over a wide range of ages, having shown good 
reliability in children as young as five. Moreover, we also believe that the 3D Reach Test 
can be applied in an elderly population, since it is performed mainly in a seated position, 
with only about 15 seconds of standing.   
4.4 PAPER IV 
The most important observations of Paper IV were these: 1) Contrary to the intended 
clinical outcome, the ambulatory activity of children with CP declines following BoNT-A 
injection into the legs. 2) Contrary to clinical goals, accelerometer-based follow-up reveals 
that arm swing does not improve and the arms do not become more similar with respect to 
quantity of motion following BoNT-A treatment of the arm most affected. 3) These effects 
were not discovered in connection with routine clinical follow-up.  
 
Prior to the BoNT-A injections, the mean percentage of time the entire group spent 
performing ambulatory activity was 5.6%. Contrary to the treatment goal three weeks after 
injections into the legs, this value had declined to 4.7%, and was 3.9% after three months a 
30% reduction in a value that was already quite low. One possible explanation is that the 
weakness experienced was unfamiliar, since a feeling of overly weak muscles is one of the 
typical undesirable side-effects of BoNT-A reported [158, 159]. Naturally, a further decline 
in ambulation by these patients, who are already sedentary, is undesirable and probably 
enhances the risk of chronic detrimental effects on health. 
 
Treatment of the legs with BoNT-A is designed to improve gait by reducing spasticity, as 
well as an unopposed strength of the muscles injected. Equinus is diminished by injecting 
the gastrocnemius and soleus muscles and knee extension improved by injecting the 
hamstrings muscles. Contrary to our own hypothesis, injection of leg muscles did not alter 
the acceleration of the waist during ambulatory activity nor did we see any decline in the 
asymmetry of arm swing. In children whose more affected non-dominant arm was injected, 
this arm exhibited significantly lower acceleration than the dominant arm during 
ambulatory activity, whereas there was no such difference among those receiving treatment 
in the legs only. Although BoNT-A was injected into the more affected, non-dominant arm 
primarily to reduce arm flexion during walking and thus make arm swing more 
symmetrical, unfortunately, these injections did not improve the symmetry of arm swing. 
 
BoNT-A was injected into the non-dominant, more severely affected arm to make it a better 
helping hand and improve movement. After such injection, the dominant arm was used 
21% more for voluntary activity than the non-dominant arm, versus 2.5% for the 
corresponding value without injection. Three weeks and three months after injection into 
the non-dominant arm, the time the dominant and non-dominant arms were engaged 
increased and decreased slightly respectively, although not significantly. Acceleration of 
the dominant and non-dominant arm was similar prior to injection and had not changed 
significantly at the time of follow-up. Thus, these children demonstrated a larger difference 
between the arms with respect to time spent performing voluntary activity than those who 
had indications for BoNT-A injection into the legs only.  
 
This finding confirms the indications for treatment, but in contrast to our hypothesis, 
BoNT-A injection into the arm more affected did not enhance its use. This absence of any 
BoNT-A treatment effect on arm usage for voluntary activity, could be due to muscle 
weakness and/or pain, another common side-effect following BoNT-A injections [158, 
159]. On the other hand, BoNT-A is also used to treat pain and in this context is believed to 
act both by directly reducing spasticity and through pharmacological pathways [161]. 
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An alternative explanation could involve an effect of BoNT-A on the central nervous 
system, which has been suggested to occur via modulation of intrafusal fibers in the 
muscles injected. This would, in turn, influence sensory afference to the spinal cord, the 
brainstem and cortical areas. With altered spindle activity, feedback would likely alter the 
spinal and cortical circuitry, thereby also affecting muscles other than the ones initially 
injected [162]. In addition to such reorganization of the central nervous system, BoNT-A 
appears to exert direct actions on the spinal cord that probably involve axonal trafficking of 
active neurotoxin, since there is no evidence that therapeutic doses of BoNT-A injected 
intramuscularly can cross the blood-brain barrier [162]. Mazzocchio and co-workers [163] 
have proposed that BoNT-A may change the excitability of spinal pathways or cause 
central chemo-denervation via retrograde axonal transport to the spinal cord.  
 
For children with indications for injection of BoNT-A into the arm, the time spent 
performing bimanual activity (as a percentage of the total time spent in voluntary activity) 
was longer both before and after injection than for children receiving BoNT-A in the legs 
only. For children injected into the non-dominant arm, the time spent performing bimanual 
activity did not change. However, for those treated in the legs only, the proportion of 
voluntary bimanual activity had risen three weeks later. We also know that these children 
walked less at this same time-point, so one possible interpretation is that when the effect of 
the BoNT-A is maximal, the children prefer to play sitting down than on foot.  
 
Three weeks after being injected in one or both legs and one arm, the difference in the 
acceleration of the arms during bimanual activity by children with CP had increased 
whereas after treatment of the legs only, there was no such difference. One possible 
explanation for this surprising finding, the opposite of what was expected, is the occurrence 
of mirror movements described in Paper 1 above.  
 
A review of the medical records revealed that for those children who received BoNT-A 
injections in the legs only, the arms were not evaluated specifically. Moreover, for the 
children injected in the non-dominant arm, the non-injected dominant arm was not 
evaluated.  
 
In summary, we demonstrate here that monitoring children with CP in their own home and 
school environment with accelerometers following BoNT-A injections provides novel and 
valuable information not obtained through routine clinical follow-up. Three weeks after 
such injection into the legs the children walked less and their capacity for walking had not 
recovered by the three-month follow-up. Neither the observed difference between the arms 
with respect to time spent in voluntary activity nor arm swing symmetry during ambulation 
were altered by injections into the most paretic arm. We recommend future characterization 
of both remote and generalized effects of BoNT-A injections.  
4.5 PAPER V 
The main findings of Paper V were the following: 1) Parents reported comparable effects of 
similar duration with few, similar and transient side-effects when Botox® was replaced by 
Dysport® (with a conversion factor of 1:2). 2) The procured cost per treatment was 4029 
SEK for Botox® and 41% lower (2380 SEK) for Dysport®.  
 
A total of 170 children, 159 with CP, received treatments in connection with 341 visits to 
the hospital during the study period, with reports 176 treatments with Botox® and 111 
treatments with Dysport®. Of the 16 arm muscles injected, the biceps brachii, adductor 
pollicis and flexor carpi ulnaris were treated most often. In the case of the legs, the three 
muscles most injected out of 14, were the gastrocnemius, hamstrings and gracilis.  
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The treatment goals were functional improvement in 190 cases, facilitation of activities of 
daily living in 35 and pain reduction in 29. In 87 cases, two or more goals were combined 
with pain reduction being one of these goals in 85% of these children. Botox® was injected 
into 89 patients at an average dose of 9.4 (SD, 3.22) U/kg body weight. Dysport® was 
injected into 252 patients at an average dose of 18.4 (SD, 6,55) U/kg body weight, i.e., the 
conversion factor of 1:2 was achieved. Parents reported comparable effects of similar 
duration for these two BoNT-A products. Side-effects were reported after 9/176 injections 
of Botox® and 5/111 injections of Dysport® with weakness and transient pain being most 
common. No less than 99.3% of the information targeted was actually collected.  
 
The annual cost for BoNT-A was 1,120,021 SEK in 2014 and 716,267 SEK in 2015. The 
cost per treatment was 4029 SEK for Botox® and 2380 SEK for Dysport®. Botox® and 
Dysport® were equal in reported effect and duration in children with CP when Dysport® 
was diluted to a concentration of 100 U/ml and injected at a dose twice as high as with 
Botox®. This conversion factor of 1:2, lower than in many previous studies, resulted in a 
cost reduction of 41%. A similar cost reduction of 37% was found when adults with 
cervical dystonia were treated with Dysport® instead of Botox® (conversion factor 2:1) 
[203]. The expense could have been reduced even more if Dysport® could be obtained in 
vials containing less than 300 U. Botox® was available in vials containing smaller amounts, 
resulting in less waste.  
 
After dilution to 100 U/ml the volume of Dysport® injected was the same as for 50 U/ml 
Botox®. The effect of different dilutions of BoNT-A is under debate. Both animal and 
human studies indicate that more extensive dilution enhances the efficacy of each U of 
toxin by increasing the volume administrated and thereby the extent of diffusion [204-206]. 
However, other studies, including two on children with spastic CP [207, 208], have 
concluded that the efficacy is independent of dilution [207, 209, 210]. Injection of larger 
volumes can be more painful and has been reported to give more side-effects due to the 
spread of toxin to nearby muscles [207, 210]. 
 
We conclude that replacing Botox® with Dysport® reduces cost by 41% with no loss in the 
magnitude or duration of effect, maintenance of safety and without any increase in 
associated costs. Our study population was relatively large, including all children with CP 
among a well-defined one-fourth of the entire Swedish population who received BoNT-A. 
Even though parents were asked about the effect of previous treatments, a standard aspect 
of care, the study design was prospective. 
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5 LIMITATIONS 
Even though CP is the most common cause of physical disability in children, it is difficult 
to collect large numbers of skeletal muscle biopsies, since the children often need to be 
anaesthetized or sedated in this connection. The best opportunity is in conjunction with 
surgery or injection of botulinum toxin. However, with an incidence of 2-3/1000 children in 
combination with the criteria for anesthesia or sedation, few children with CP are eligible. 
The large variations in disease severity and muscle composition also require a larger 
number of subjects than we had to obtain sufficient statistical power. Control biopsies from 
TD children are also difficult to obtain for the same reasons. Collecting biopsies from 
muscles exposed during open reduction of dislocated fractures is complicated, since these 
operations are often performed outside office hours. 
 
Cross-sectional studies on muscle samples from children with CP and contracture formation 
of differing severity indicate progression of this pathology, although the inter-individual 
variability is extensive. Moreover, to follow actual morphological changes, muscle samples 
should be collected from the same muscle of the same child repeatedly and few children 
undergo repeated surgical procedures that provide access to the same muscle.  
 
The muscles of the body differ in many respects, and biopsies from different muscles must 
be compared with caution. Sometimes a group of muscles with similar function can be 
combined, but comparing corresponding muscles from children with CP and TD children is 
preferable. The muscle composition also changes as the child grows and information on 
development in association with puberty can provide valuable insights. 
 
Specific limitations of the present studies:  
 
In Paper I, the control children were slightly younger (mean age 10, range 7-13 years) than 
the those with CP (mean age 14, interval 8-17 years). At the department where this research 
was conducted, trauma in children younger than 15 is treated and, therefore, no TD children 
older than over 14 years of age could be included. At this same department, children with 
CP are treated until the age of 18. Tendon transfers in the forearm are usually performed on 
older teenagers with CP.  
 
Biopsies were taken only from muscles directly accessible during surgery (open fracture 
reduction or tendon transfer), so that these biopsies derived from slightly different muscles. 
All muscles in the human body demonstrate their specific phenotypes, but the FCU and 
FCR, as well as ECRB and ECU have similar functions and architecture and could 
therefore be grouped.  
 
With the SDS-PAGE procedure employed, small amounts of developmental myosin are 
difficult to distinguish from other forms of MyHCs. Earlier immunohistochemical 
investigations techniques have revealed that children with CP have more very small fibers 
expressing developmental myosin in their wrist and elbow flexors than control [45, 47]. 
These small cells were interpreted as an indication of ongoing regeneration, rather than 
immaturity, since all larger cells expressed only mature MyHC. However, the net amount 
of developmental myosin in spastic flexors was very small. 
 
 
In Paper II, we included both patients with CP and acquired brain injury (ABI). We did so 
because the two patients with ABI suffered their injuries at a young age (7 and 8 years), had 
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similar fixed contractures and were considered candidates for a similar surgical procedure. 
Control biopsies were taken at autopsy within 24 hours of death. 
 
Paper IV is limited by the small number of patients, the heterogeneity of the subtype of CP, 
and the variation in age and muscles injected, reflecting the variety of patients treated at our 
department. In addition, some data were lost due to technical problems with the 
accelerometers and the failure of some children to participate in the entire follow-up.  
 
In Paper V, the effect of treatment was reported by the parents, i.e., not in an objectively 
measurable manner. The five experienced pediatric orthopedic surgeons who participated 
had slightly different ways of describing the goals that the parents, children and treating 
physician, physiotherapists and occupational therapists agreed upon. Analyses related 
specifically to goal fulfillment were therefore difficult to perform. 
 
Paper V could not have a blinded design, since we were required to inform the parents and 
children about the change in products. In addition, the entire multi-professional team was 
aware of the change in brand, since all underwent training about dosing and diluting the 
new drug to ensure patient safety. Neither the parents, children nor staff involved expressed 
any expectation or hope of anything more than a neutral effect of the product change, which 
could result in expectation bias.  
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6 SUMMARY AND CONCLUSIONS 
 
The major findings described here are as follows:  
6.1 PAPER I 
• The wrist flexors of children with CP contain a higher proportion of the fast and 
fatigable MyHC IIx isoform than TD children.  
• Wrist flexors contain a higher proportion of MyHC IIx than wrist extensors.  
• The wrist flexors of children with CP contain a lowered proportion of the fast MyHC 
IIa isofrom.  
• Wrist flexors contain a lower proportion of MyHC IIa than wrist extensors.  
• The wrist extensors of children with CP contain a lower proportiopn of the slow 
MyHC I isoform.  
 
Both their brain injury and the various requirements imposed on the flexors and extensors 
of the wrist affect the expression of MyHC in children with CP. Reduced voluntary usage of 
the arms and a partial alteration in neuronal signaling from the injured brain can both 
contribute to the elevated levels of MyHC IIx seen in these children.  
6.2 PAPER II 
• The biogenesis of ribosomes is impared in the skeletal muscle of children with CP.  
• The expression of genes encoding pro-inflammatory cytokines is elevated in this 
same tissue.   
• The number of satellite cells in the skeletal muscle of children with CP is reduced. 
• More intramuscular collagen surrounds bundles of muscle fibers and the levels of 
transcripts of genes involved in collagen production are higher in this same tissue.  
 
The underlying cause of contracture development in children with CP is their brain injury 
and the consequent alteration in neuronal signaling. Pro-inflammatory cytokines may 
mediate both reduced growth and undesirable production of extracellular matrix in 
connection with such development of muscle contractures and decreased production of 
ribosomes may also be a contributing factor. The finding of fewer satellite cells and an 
elevated amount of intramuscular collagen in the biceps brachii muscle of children with CP 
are consistent with previous findings on other muscles of these patients.  
6.3 PAPER III 
• The 3D Reach Test for the arms demonstrates excellent inter- and intra-session 
reliability in TD children.  
• This 3D reach Test shows excellent feasibility and reliability in a pilot study on five 
young adults with CP.  
• The results are independent of which arm is dominant in the case of TD children, 
but indicates a clear side difference in individuals with unilateral CP.  
 
The 3D Reach Test for the arms demonstrates excellent inter- and intra-session reliability, 
excellent feasibility and takes only 10 minutes to perform with no discomfort to the subject. 
We recommend the 3D Reach Test for use in clinical practice, as well as for investigating 
e.g., the efficacy of an intervention.  
 30 
6.4 PAPER IV 
• Accelerometer-based follow-up reveals that, contrary to the intended clinical 
outcome, ambulatory activity declines following BoNT-A injection into the legs.  
• Contrary to clinical goals, such follow-up shows that arm swing does not improve and 
the arms do not become more similar with respect to quantity of motion following 
BoNT-A treatment of the arm most affected.  
• These effects were not discovered through routine clinical follow-up.  
Monitoring children with CP in their own home with accelerometers following BoNT-A 
treatment reveals previously unknown effects on physical activity that are not detected by 
routine clinical follow-up. 
6.5 PAPER V 
• The parents of children with CP report effect of similar magnitude and duration, with 
few, similar and transient side-effects following the replacement of Botox® with 
Dysport® for treatment of spasticity and pain.  
• The cost per treatment was 4,029 SEK for Botox® and 2,380 SEK for Dysport®. 
 
When Botox® was replaced by a dose of Dysport® twice as high, the parents of children 
with CP perceived the treatment to be equally effective, while the procured cost was 
lowered 41%.  
 
The results of Paper I regarding MyHC expression in the muscles of children with CP are 
proposed to reflect altered neuronal signaling, differences in muscular requirements and 
reduced activity due to established contractures. Whether the enhanced level of MyHC IIx 
in these muscles is caused by the reduced voluntary usage of the arms remains to be proven. 
Increased usage might favor the expression of the MyHC I and MyHC IIa isoform which 
could potentially promote endurance.  
 
The several potential causes of skeletal muscle contractures found in Paper II include 
reduced biogenesis of ribosomes, enhanced expression of genes encoding pro-inflammatory 
cytokines, reduced numbers of satellite cells, higher levels of transcripts of genes involved 
in collagen production and the larger amount of collagen surrounding bundles of muscle 
fibers.  
 
Previous evaluations of functional gains by children with CP from BoNT-A treatment have 
shown varying results, although reduction of spasticity is usually observed. Paper III and 
IV describe novel and promising approaches to evaluating such treatment. Paper IV reveals 
that treatment with botulinum toxin can give rise to unexpected and sometimes undesirable 
effects which should be taken into account when planning follow-up. Particularly if the 
treatment goals are functional gain, assessment of muscles and/or limbs not injected should 
be included in the evaluation.  
 
Furthermore, BoNT-A treatment is expensive in terms of both the cost of the drug itself and 
the cost for the staff involved in the injection, follow-up and training post-treatment. In 
Paper V, we have shown that the cost of the drug can be reduced by more than 40% with 
preserved effect and duration simply by switching to another product, thereby freeing up 
more resources for training and follow-up.  
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7 FUTURE PERSPECTIVES 
In order for us to understand contracture development in children with CP more has to be 
done. I believe that repeated biopsies from the same child during childhood and 
adolescence could give more valuable insights into the mechanisms underlying contracture 
formation. Today, we do not know whether the biochemical and histological changes that 
we observe in CP muscle are the cause or the consequence of the contracture.  
 
Spasticity peaks at about four years of age and then gradually levels out at the age of 12 
[53]. Contracture formation however, starts early and continues progressively during 
growth, with more rapid development during puberty [54, 55, 57]. The early biopsy most 
likely holds the key to understanding contracture formation. Muscle sampling at a young 
age would enable a comparison between muscle before and after the establishment of a 
fixed contracture that would give us information on the state of the muscle before the 
development of the contracture. Tentative findings to explore further in young CP muscle is 
for example the increased levels of TNF and IL-6 and the reduced biogenesis of ribosomes 
that we found in muscle with fixed contractures. 
 
Detailed information on the effects of BoNT-A on muscle, especially repeated injections, in 
children with CP is also warranted. We know that the short-term effect of BoNT-A is 
reduced spasticity [137, 146-148] and that BoNT-A initially increases the ROM even if the 
obtained ROM cannot be preserved over time [155]. Rather than one leading to the other, 
spasticity and contracture development seem to be two parallel phenomena, as contracture 
development continuous despite substantial and permanent spasticity reduction through e.g. 
SDR [211]. Important questions to answer are whether the process of contracture 
development is just so strong that it overruns efforts to prevent the development of a 
contracture or if BoNT-A treatment, in worst case, could even accelerate the development. 
Contrary to what could be expected, studies on rats following BoNT-A injection have 
shown an increased gain of the stretch reflex by an increased excitability of spinal motor 
neurons actually counteracting the intended spasticity reduction [212]. An increased muscle 
stiffness has also been found [213].  Whether the same findings also happen in humans 
remain to be proven. Furthermore, it’s also of great importance to elucidate if BoNT-A 
treatment affects skeletal muscle growth and/or ECM production, processes affected in 
skeletal muscle with contractures.  
 
To answer some of the questions above we have collected a unique material with repeated 
biopsies from the biceps brachii and gastrocnemius muscles of children with cerebral palsy. 
The first biopsy was taken prior to the initiation of BoNT-A treatment from BoNT-A naïve 
skeletal muscle. Follow-up biopsies were taken 3-6 and approximately 12 and 24 months 
after the first BoNT-A injection in conjunction with the next injection. As spasticity is often 
high at young age and contractures typically develop somewhat later in life, the first biopsy 
was often collected before a fixed contracture was established. To be able to answer 
mechanistic questions on the BoNT-A effect, ideally, repeated biopsies from children with 
CP but without BoNT-A injections should also be collected. However, as surgery on i.e. 
gastrocnemius or biceps brachii muscles are performed after the establishment of a 
contracture consecutive biopsies from early age without any relation to treatment is difficult 
to obtain. Animal studies could be an alternative, but also poses problems as there still is no 
ideal animal model for CP. 
 
As satellite cells are important for skeletal muscle growth [89, 90] but also play a role in the 
regulation of ECM production [93, 94], these cells are of great interest for the study of 
contracture development in children with CP. Recently, Domenighetti and co-workers 
[214] showed a loss of myogenic potential for satellite cells isolated from CP muscle. The 
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authors speculate that this was due to altered expression of genetic programs associated 
with muscle stem cell differentiation and muscle fiber formation, plausibly conditioned by 
an alternative DNA methylation pattern. Further, Fry and collaborators [94] demonstrated 
that satellite cells communicate with interstitial fibro-genic cells to ensure a proper ECM 
production in skeletal muscle during hypertrophic growth through the secretion of 
exosomes. Whether these two processes are involved in contracture formation in skeletal 
muscle of children with CP are still unexplored. In the future, research efforts should be 
focused on comparisons between muscle of children with CP and TD children as well as 
comparisons of muscle with and without a fixed contracture with respect to e.g. epigenetic 
mechanisms. Several layers of regulatory mechanisms control gene expression including 
DNA methylation as studied by Domenighetti et al, but also other potential mechanisms 
such as histone modification through acetylation and/or methylation and RNA interference 
via miRNAs. With more knowledge on the epigenetic modifications of satellite cells and 
the communication between satellite cells and fibro-genic cells there might be a potential 
way of inhibiting contracture development in the future.  
 
The 3D Reach Test shows promising results on reliability and feasibility in both TD 
children and young adults with CP, which is an inspiration for further development of the 
test. Further reliability tests may be warranted in younger children, both TD and with CP, to 
establish reliability across a wider age span. The 3D Reach Test could also be of interest in 
in an elderly population, warranting evaluation in this group also. Given the excellent 
reliability we have found in our test group, good or excellent reliability in other groups can 
be expected. Once reliability is confirmed for an age-group, evaluation on treatment might 
follow in different diagnosis with restricted arm movement.  
 
Further, we need to perform a study for the clinical use and interpretability of the test in 
children with CP. We plan to compare our new 3D Reach Test to already available clinical 
tests in order to examine whether an existing test, or part of an existing test, could be 
replaced or whether the 3D Reach Test adds information to that gained from other tests. 
Melbourne Assessment 2 (MA2) provides the possibility to analyze the elements “Range of 
movement” and “Accuracy of reach” separately [112] in children 2.5-15 years of age, 
making the MA2 a good candidate for a bench-mark test for the proposed comparison. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Cerebral pares (CP) är den vanligaste orsaken till fysiskt rörelsehinder i världen idag. 
Termen CP används idag som ett paraplybegrepp för bestående avvikelser avseende rörelse 
och hållning samt problem med kommunikation, kognition, tolkning av sinnesintryck och 
varseblivning till följd av en skada som drabbat den omogna hjärnan. Hjärnskadan kan 
uppstå under fosterstadiet, i samband med förlossning eller under de första levnadsåren. 
Trots att hjärnskadan i sig är icke-progressiv, yttrar den sig på olika sätt i rörelseapparaten i 
olika åldrar.  
 
Minskad ledrörlighet och ökat muskelmotstånd vid passiv rörelse är vanligt. Spasticitet, en 
komponent i det ökade rörelsemotståndet, är som störst runt fyra års ålder. Minskad 
ledrörlighet, också kallat kontraktur, utvecklas under hela barndomen och tonåren. Orsaken 
till minskad ledrörlighet vid CP är inte känd. För att i framtiden bättre kunna behandla, och 
kanske i framtiden förebygga minskad ledrörlighet, behöver vi få mer kunskap om vad som 
händer i muskeln när rörligheten försämras. I denna avhandling ingår två arbeten som 
beskriver muskler hos barn med CP.  
 
Många olika insatser görs för att hjälpa barn med CP till bättre rörelse och självständighet. 
Korrigering av skelett och mjukdelar med ortopedisk kirurgi är en, att minska spasticitet i 
muskler med botulinumtoxin en annan och träning ytterligare en insats. Oavsett behandling 
är det viktigt att följa upp resultatet för att kunna planera den fortsatta behandlingen och 
utveckla behandlingen av barn med CP. I denna avhandling har vi vidareutvecklat och 
testat upprepbarheten i ett utvärderingsinstrument som mäter tredimensionell räckvidd i 
armarna på barn utan rörelsehinder. Vi har även testat metoden på unga vuxna med CP. 
Vidare har vi utvärderat botulinumtoxin-behandling av barn med CP på ett nytt sätt genom 
att med fyra stycken rörelsemätare före och efter behandling följa dem under fyra dagar i 
deras hem- och skol-miljö.  
 
Botulinumtoxin-behandling av barn med CP är en dyrt och det är tidskrävande för både 
barn, föräldrar och vårdpersonal. För att använda våra resurser så effektivt som möjligt, inte 
minst för att göra behandlingen tillgänglig för alla som behöver den, har vi ett ansvar att 
göra det så billigt och kostnadseffektivt som möjligt med bibehållen kvalitet. Priset på 
botulinumtoxin är en aspekt att ta hänsyn till. I denna avhandling har vi genomfört ett 
kontrollerat byte från ett dyrare till ett billigare botulinumtoxin samtidigt som vi följt upp 
behandlingseffekten, hur länge medicinen verkar och om den nya behandlingen har fler 
eller andra biverkningar än den tidigare.  
 
Det viktigaste jag har kommit fram till i min avhandling är följande: 
• Signalsubstanser som normalt verkar vid inflammation (proinflammatoriska 
cytokiner) skulle kunna ha en roll i utvecklingen av minskad ledrörlighet hos barn 
med CP genom att både hämma muskeltillväxt och att göra muskeln styvare genom 
att stimulera bildningen av bindväv i muskeln.  
• Minskad muskeltillväxt hos barn med CP skulle kunna orsakas av en försämrad 
produktion av protein till följd av försämrad funktion i muskelcellens ”proteinfabrik” 
(ribosomen).  
• Bicepsmuskeln i överarmen hos barn med CP innehåller ett minskat antal 
muskelstamceller (satellitceller) och en ökad mängd bindväv mellan 
muskelfiberbuntarna.  
• Det nya testet för att mäta tredimensionell räckvidd uppvisar en hög upprepbarhet hos 
barn utan rörelsehinder och en mycket hög upprepbarhet för unga vuxna med CP samt 
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en mycket hög genomförbarhet i båda grupperna. Det nya testet är snabbt och enkelt 
att genomföra.  
• En alternativ uppföljning av barn med CP som fått behandling med botulinumtoxin 
med fyra stycken rörelsemätare (accelerometarar) fångar förändringar som traditionell 
uppföljning på sjukhus missar. Till exempel så minskar aktiviteten till fots tre veckor 
efter behandling och denna nedgång består fortfarande efter tre månader.  
• Vi har visat att vi genom bytet från ett botulinumtoxin (Botox®) till ett annat 
(Dysport®) kunde reducera läkemedelskostnaden med 41% med bevarad effekt, 
bevarad tid för effekten och utan att biverkningsprofilen ändrades.  
I vårt fortsatta arbete hoppas vi kunna bringa ytterligare klarhet i varför ledrörligheten 
minskar hos barn med CP genom att ta ett muskelprov från samma barn vid flera tillfällen 
och helst med ett första muskelprov taget innan ledrörligheten påverkats. Detta skulle ge 
oss möjlighet att bättre avgöra vad av våra, och andras, tidigare fynd som är orsak till den 
minskade ledrörligheten och vad som är en konsekvens av den samma.  
 
Vidare hoppas vi i framtiden kunna svara på frågan om huruvida injektioner med 
botulinumtoxin, särskilt upprepade sådana, påverkar antalet muskelstamceller, muskelns 
tillväxt eller produktionen av bindväv i muskeln. Muskelstamcellernas roll behöver även 
utredas vidare såtillvida att vi behöver lära oss mer om hur tidpunkten för hjärnskadan vid 
CP påverkar muskelstamcellernas funktion och antal och om barn med CP har färre 
muskelstamceller från början eller om de förlorar stamceller successivt under uppväxten. Vi 
hoppas också kunna utreda om de signalsubstanser som normalt verkar vid inflammation 
påverkar tillväxten i såväl muskel som i skelettets tillväxtzoner.  
 
Det tredimensionella testet för räckvidd behöver testas vidare för yngre barn utan 
rörelsehinder och för barn och ungdomar med CP för att bekräfta användbarheten i dessa 
grupper. En undersökning behöver också göras för att bekräfta att det nya testet kan ersätta 
andra mer tidskrävande tester för att senare kunna komma i klinisk användning.  
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